Navigation Links
Treatment corrects severe insulin imbalance in animal studies
Date:7/31/2008

osing such lesions and performing the curative surgery on newborns.

However, when abnormal cells are distributed throughout the pancreas in so-called diffuse HI, surgeons must remove nearly all the pancreas. This relieves HI in about a quarter of cases, but leaves the majority of patients at high risk for insulin imbalance, in which blood glucose levels are too low (hypoglycemia) or too high, resulting in diabetes.

The new study makes use of a peptide (an amino acid compound) called exendin-(9-39) that blocks the action of a specific hormone receptor in beta cells. Building on their previous work using exendin-(9-39) on normal mice, De Len's study team studied the peptide's effect on a strain of mice that had been genetically engineered to mimic the defect found in children with congenital HI.

When researchers withhold food from those mice, their blood glucose levels become low, a condition called fasting hypoglycemia. Mice who had received exendin-(9-39), however, had significantly higher levels of fasting blood glucose compared to mice that were not treated with the peptide, and reached levels comparable to those in normal, healthy animals. Further studies identified the mechanisms in the hormone signaling system that malfunctions in HI.

The next step, says De Len, is a pilot study now under way to test the effect of exendin-(9-39) in children and adults with congenital HI. If results from the pilot study are promising, her study team expects to progress to a larger clinical trial. "If this peptide can be developed into a treatment for children with this common form of HI, we may have a new tool for controlling their insulin levels and managing their disease," added De Len.

The Congenital Hyperinsulinism Center at Children's Hospital has worldwide prominence in diagnosing and treating this genetic disease. Much of its work builds on pioneering research by Charles A. Stanley, M.D., in identifying the specific gene defec
'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6050
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Video released of rapid Alzheimers improvement after new immune-based treatment
2. Fertility treatment in developing countries; a cycle of IVF for less than $200
3. New treatment approach promising for lymphoma patients in the developing world
4. Treatment delays result in poor outcomes for men with breast cancer
5. Counting tumor cells in blood predicts treatment benefit in prostate cancer
6. Stroke study reveals key target for improving treatment and suggests that Gleevec may help
7. Hypertension treatment effective in reversing vascular damage
8. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
9. Source of drug-tolerant tuberculosis possibly behind TB relapses, intensity of treatment
10. Novel therapeutic strategy for colon cancer treatment
11. New ballast treatment could protect Great Lakes fish
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... 4, 2014) While adults make up 95 percent of ... study from the University of Colorado School of Medicine shows ... health concern. The study, published recently in the ... several important aspects of adult vaccination. Every year, 30,000 ...
... 2014 - A recent prospective study published in ... novel simplified laboratory method of culturing embryos suggested that ... system when compared with those reported by conventional IVF ... this new method. According to the results of this ...
... A UT Arlington bioengineer has received a four-year, $1.4 ... nanoparticle system to shore up arterial walls following angioplasty ... Nguyen, a UT Arlington associate professor of bioengineering, said ... angioplasty, which opens arteries and blood vessels that are ...
Cached Biology News:Thousands of unvaccinated adults die each year from preventable diseases 2First live births with a novel simplified IVF procedure 2UT Arlington bioengineer to create new nanoparticle system to shore up arterial walls 2
(Date:8/3/2015)...  ArroGen Group, an integrated advanced forensic solutions ... (FMID) technology Aug. 2-8 at the International Association ... Calif. FMID, a new ... agents, district attorneys and government agencies to build ... By analyzing chemical residues on fingerprints taken from ...
(Date:8/3/2015)... 3, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... th Annual Canaccord|Genuity Growth Conference in ... and CEO, William C. Taylor , President and ...
(Date:8/3/2015)... 3, 2015  Merck KGaA, Darmstadt, Germany ... high-tech products in the healthcare, life science and performance ... Nano-C, their development and launch of promising new fullerene ... Merck KGaA, Darmstadt, Germany , is ... sector. Novel derivatives: highly stable, easy to ...
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Aethlon Medical, Inc. ... biofiltration devices to treat life-threatening diseases, today announced that ... conference call and webcast on Thursday, August 13, 2015 ... and webcast will follow the release of fiscal 2016 ... will be available approximately two hours after the call ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2
... , , , , , ... One,Medical, Inc. ("China Sky One Medical" or "the Company") ... developing and producing,over-the-counter drugs in the People,s Republic of ... that will be included in the 2009,Edition of the ...
... The Mosaic Company (NYSE: MOS ) plans to issue ... on Tuesday, January 5, 2010, after the close of trading on ... Mosaic,s website at mosaicco.com/investors. , The Company will host ... to discuss the results. The call will begin at 11:00 ...
... , , , , , , , ... - 45 Patients Enrolled in Study Designed to Evaluate the Ability ... Cardio3 BioSciences, a leading Belgian biotechnology company specialising,in cell-based therapies for ... months ahead of schedule,enrolment in the first stage of its pivotal ...
Cached Biology Technology:China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3
... ( Abpromise for all tested applications). ... to amino acids 14/26 of Mouse Green cones ... acids 18/30 of tiger red cones opsin 1 ... Entrez Gene ID: 5956 ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Wnt-1 (G-19)...
Biology Products: